{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CLL%2C+Refractory&page=2",
    "query": {
      "condition": "CLL, Refractory",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CLL%2C+Refractory&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T08:32:27.081Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00334438",
      "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "yttrium Y 90 ibritumomab tiuxetan",
          "type": "RADIATION"
        },
        {
          "name": "Indium 111 ibritumomab tiuxetan",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 12,
      "start_date": "2006-07",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2016-12-23",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 2,
      "location_summary": "Hackensack, New Jersey • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00334438"
    },
    {
      "nct_id": "NCT00933985",
      "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Leukemias of Ambiguous Lineage",
        "Acute Undifferentiated Leukemia",
        "Angioimmunoblastic T-cell Lymphoma",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Childhood Burkitt Lymphoma",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Diffuse Large Cell Lymphoma",
        "Childhood Immunoblastic Large Cell Lymphoma",
        "Childhood Nasal Type Extranodal NK/T-cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Noncutaneous Extranodal Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Anaplastic Large Cell Lymphoma",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Relapsing Chronic Myelogenous Leukemia",
        "Small Intestine Lymphoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "dexrazoxane hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "obatoclax mesylate",
          "type": "DRUG"
        },
        {
          "name": "liposomal vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 22,
      "start_date": "2009-06",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2014-05-01",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00933985"
    },
    {
      "nct_id": "NCT00081887",
      "title": "Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 8,
      "start_date": "2004-05",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081887"
    },
    {
      "nct_id": "NCT01118013",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "donor lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "reduced-intensity transplant conditioning procedure",
          "type": "OTHER"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-12",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 10,
      "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Elkton MD",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01118013"
    },
    {
      "nct_id": "NCT02594384",
      "title": "A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic"
      ],
      "interventions": [
        {
          "name": "LAM-002A",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OrphAI Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2015-10",
      "completion_date": "2023-03-30",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 11,
      "location_summary": "Huntsville, Alabama • Jacksonville, Florida • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02594384"
    },
    {
      "nct_id": "NCT00949052",
      "title": "Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "medical chart review",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "evaluation of cancer risk factors",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2009-01",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2018-08-16",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00949052"
    },
    {
      "nct_id": "NCT00551239",
      "title": "Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "pixantrone dimaleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CTI BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 0,
      "start_date": "2007-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551239"
    },
    {
      "nct_id": "NCT04512105",
      "title": "Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Chronic Lymphocytic Leukemia",
        "AML, Adult",
        "CLL",
        "CLL, Relapsed",
        "CLL, Refractory"
      ],
      "interventions": [
        {
          "name": "Pitavastatin",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-12-02",
      "completion_date": "2025-02-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04512105"
    },
    {
      "nct_id": "NCT00082888",
      "title": "Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Nodal Marginal Zone Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult T-Cell Leukemia/Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Splenic Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2004-03-24",
      "completion_date": "2017-07-05",
      "has_results": true,
      "last_update_posted_date": "2020-04-13",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Rochester, Minnesota",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082888"
    },
    {
      "nct_id": "NCT00095797",
      "title": "XK469R in Treating Patients With Refractory Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Basophilic Leukemia",
        "Adult Acute Eosinophilic Leukemia",
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Anemia With Excess Blasts",
        "Refractory Anemia With Excess Blasts in Transformation",
        "Refractory Chronic Lymphocytic Leukemia",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "R(+)XK469",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2004-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-08",
      "last_synced_at": "2026-06-11T08:32:27.081Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00095797"
    }
  ]
}